Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $5.0 million.

  • Adma Biologics' Share-based Compensation rose 5876.06% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.1 million, marking a year-over-year increase of 10212.53%. This contributed to the annual value of $13.6 million for FY2024, which is 12007.43% up from last year.
  • Adma Biologics' Share-based Compensation amounted to $5.0 million in Q3 2025, which was up 5876.06% from $5.0 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Share-based Compensation ranged from a high of $5.4 million in Q4 2024 and a low of $688274.0 during Q3 2021
  • Moreover, its 5-year median value for Share-based Compensation was $1.6 million (2022), whereas its average is $2.3 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first tumbled by 3237.43% in 2023, then skyrocketed by 21134.67% in 2024.
  • Over the past 5 years, Adma Biologics' Share-based Compensation (Quarter) stood at $1.2 million in 2021, then dropped by 11.88% to $1.1 million in 2022, then skyrocketed by 63.23% to $1.7 million in 2023, then soared by 211.35% to $5.4 million in 2024, then dropped by 7.1% to $5.0 million in 2025.
  • Its Share-based Compensation was $5.0 million in Q3 2025, compared to $5.0 million in Q2 2025 and $4.6 million in Q1 2025.